Related Experiment Video
Updated: May 5, 2026
08:34
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
6.9K
[Correlation between plasma aldosterone concentration and left ventricular structure in hypertensive patients]
Yu-jie Zhang1, Nan-fang Li, Ju-hong Zhang
1Hypertension Department of People's Hospital of Xinjiang Uygur Autonomous Region. The Center of Diagnosis, Treatment and Research of Hypertension in Xinjiang, Urumqi 830001, China.
Zhonghua Xin Xue Guan Bing Za Zhi
|November 29, 2013
Summary
Plasma aldosterone concentration (PAC) is linked to increased interventricular septum thickness (IVST) and left ventricular posterior wall thickness (LVPWT) in hypertensive patients. This suggests aldosterone may play a role in hypertensive heart changes.
Area of Science:
- Cardiology
- Endocrinology
- Hypertension Research
Context:
- Hypertension is a major risk factor for cardiovascular disease.
- Left ventricular structural changes, such as hypertrophy, are common in hypertensive patients.
- Aldosterone plays a role in blood pressure regulation and cardiovascular remodeling.
Purpose:
- To investigate the correlation between plasma aldosterone concentration (PAC) and left ventricular structure in hypertensive patients.
- To determine if elevated PAC is associated with specific echocardiographic parameters of left ventricular hypertrophy.
Summary:
- A study of 201 hypertensive patients assessed plasma aldosterone concentration (PAC) and left ventricular parameters via echocardiography.
- Patients with higher PAC showed significantly increased interventricular septum thickness (IVST) and left ventricular posterior wall thickness (LVPWT).
- PAC was positively correlated with IVST and LVPWT, but not with left ventricular mass index (LVMI) or end-diastolic dimension (LVEDD).
Impact:
- This research highlights a potential link between aldosterone levels and specific structural alterations in the hypertensive heart.
- Findings may inform therapeutic strategies targeting the renin-angiotensin-aldosterone system in hypertension management.
- Further investigation into the mechanisms underlying aldosterone-induced cardiac remodeling is warranted.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
2.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
2.1K
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
891
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
891
01:29Hypertension II: Pathophysiology
1.8K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.8K
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
810
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
810
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:22Aortic Regurgitation II: Clinical Features and Diagnostic Tests
1.2K
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
1.2K